17 results on '"Castellano, D."'
Search Results
2. Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052
3. Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
4. IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)
5. Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052
6. Circulating tumor cells as a predictive marker for response in patients with metastatic castrate resistant prostate cancer treated with Radium 223
7. 1119 - FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)
8. 1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)
9. 86 - Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052
10. 94 - Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
11. 557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy
12. 212 - IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)
13. 170 - Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052
14. P091 - Circulating tumor cells as a predictive marker for response in patients with metastatic castrate resistant prostate cancer treated with Radium 223
15. 773 Analysis of molecular profiling of renal cell carcinoma (RCC). Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II
16. 295 RENAL NEOPLASMS: IS IT POSSIBLE TO DIAGNOSE THE GRADE WITH CORE BIOPSIES?
17. 48 LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC): A SINGLE INSTITUTION EXPERIENCE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.